Answers are grounded in this paper and cite their sources.
Comparative data on first-line versus second-line canakinumab following anakinra in pediatric colchicine-resistant familial Mediterranean fever (crFMF) are lacking. We compared effectiveness, flare characteristics, and flare-free survival between treatment sequences. This retrospective single-center cohort study included 89 pediatric patients with crFMF carrying biallelic pathogenic exon 10 Mediterranean Fever gene (MEFV) variants who received canakinumab for at least 6 months, either as first-line therapy (n = 48) or following anakinra (n = 41). Canakinumab significantly reduced median Pras Disease Severity Score from 8 to 6 and International Severity Scoring System for familial Mediterranean fever from 4 to 1 (both p < 0.001). Patients receiving first-line canakinumab had fewer attacks during the first 6 months (p = 0.014), lower early flare rates (2.1% vs 17.1%; p = 0.022), and a longer time to first flare (14 vs 10 months; p = 0.030) than those receiving second-line treatment. Flare-free survival tended to favor first-line treatment (35 vs 19 months; log-rank p = 0.087), while overall flare rates were similar. Most first flares occurred during dose-interval extension, particularly at 8 weeks. Canakinumab provided effective disease control regardless of treatment sequence. However, patients receiving first-line canakinumab experienced fewer early flares and a longer time to first flare compared with those receiving second-line treatment.
No takes yet. Share an insight, caveat, or question.
Çanlıoğlu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: